|
1
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer: Diagnosis, treatment and follow-up. Ann Oncol. 26:16–41.
2016. View Article : Google Scholar
|
|
2
|
Gruber S and Thompson W: A
population-based study of endometrial cancer and familial risk in
younger women. Cancer and steroid hormone study group. Cancer
Epidemiol Biomarkers Prev. 5:411–417. 1996.PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lortet-Tieulent J, Ferlay J, Bray F and
Jemal A: International patterns and trends in endometrial cancer
incidence, 1978–2013. J Natl Cancer Inst. 110:354–361. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Silverberg E, Boring CC and Squires TS:
Cancer statistics 1990. CA Cancer J Clin. 40:9–26. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gusberg SB: Diagnosis and principles of
treatment of cancer of the endometriumFemale genital cancer.
Gusberg SB, Shingleton HM and Deppe G: New York: Churchill; 337.
1988
|
|
7
|
Colombo N, Preti E, Landoni F, Carinelli
S, Colombo A, Marini C and Sessa C; ESMO Guidelines Working Group,
: Endometrial cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24:33–38. 2013.
View Article : Google Scholar
|
|
8
|
Noone A, et al: SEER cancer statistics
review, 1975–2015, national cancer instituteBethesda, MD:
https://seer.cancer.gov/csr/1975_2015/2018
|
|
9
|
Aristizabal P, Graesslin O, Barranger E,
Clavel-Chapelon F, Haddad B, Luton D, Darai E, Rouzier R and Koskas
M: A suggested modification to FIGO stage I endometrial cancer.
Gynecol Oncol. 133:192–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riess L: Zur pathologischen anatomie des
blutes. Arch Anat Physiol Wiss Med. 39:237–249. 1872.
|
|
11
|
Pedersen LM and Milman N: Prognostic
significance of thrombocytosis in patients with primary lung
cancer. Eur Respir J. 9:1826–1830. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Costantini V, Zacharski LR, Moritz TE and
Edwards RL: The platelet count in carcinoma of the lung and colon.
Thromb Haemost. 64:501–505. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ikeda M, Furukawa H, Imamura H, Shimizu J,
Ishida H, Masutani S, Tatsuta M and Satomi T: Poor prognosis
associated with thrombocytosis in patients with gastric cancer. Ann
Surg Oncol. 9:287–291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monreal M, Fernandez-Llamazares J, Pinol
M, Julian JF, Broggi M, Escola D and Abad A: Platelet count and
survival in patients with colorectal cancer-a preliminary study.
Thromb Haemost. 79:916–918. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimada H, Oohira G, Okazumi S, Matsubara
H, Nabeya Y, Hayashi H, Takeda A, Gunji Y and Ochiai T:
Thrombocytosis associated with poor prognosis in patients with
esophageal carcinoma. J Am Coll Surg. 198:737–741. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen CC, Yang CF, Yang MH, Lee KD, Kwang
WK, You JY, Yu YB, Ho CH, Tzeng CH, Chau WK, et al: Pretreatment
prognostic factors and treatment outcome in elderly patients with
de novo acute myeloid leukemia. Ann Oncol. 16:1366–1373. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki K, Aiura K, Kitagou M, Hoshimoto S,
Takahashi S, Ueda M and Kitajima M: Platelets counts closely
correlate with the disease-free survival interval of pancreatic
cancer patients. Hepatogastroenterology. 51:847–853.
2004.PubMed/NCBI
|
|
18
|
Brockmann MA, Giese A, Mueller K, Kaba FJ,
Lohr F, Weiss C, Gottschalk S, Nolte I, Leppert J, Tuettenberg J
and Groden C: Preoperative thrombocytosis predicts poor survival in
patients with glioblastoma. Neuro Oncol. 9:335–342. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gogus C, Baltaci S, Filiz E, Elhan A and
Beduk Y: Significance of thrombocytosis for determining prognosis
in patients with localized renal cell carcinoma. Urology.
63:447–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu CC, Chang KW, Chou FC, Cheng CY and Liu
CJ: Association of pretreatment thrombocytosis with disease
progression and survival in oral squamous cell carcinoma. Oral
Oncol. 43:283–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taucher S, Salat A, Gnant M, Kwasny W,
Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C,
et al: Impact of pretreatment thrombocytosis on survival in primary
breast cancer. Thromb Haemost. 89:1098–1106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ye Q, Cheng J, Ye M, Liu D and Zhang Y:
Association of pretreatment thrombocytosis with prognosis in
ovarian cancer: A systematic review and meta-analysis. J Gynecol
Oncol. 30:e52019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buergy D, Wenz F, Groden C and Brockmann
MA: Tumor-platelet interaction in solid tumors. Int J Cancer.
130:2747–2760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta GP and Massagué J: Platelets and
metastasis revisited: A novel fatty link. J Clin Invest.
114:1691–1693. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Palumbo JS, Talmage KE, Massari JV, La
Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M and Degen JL:
Platelets and fibrin (ogen) increase metastatic potential by
impeding natural killer cell-mediated elimination of tumor cells.
Blood. 105:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sierko E and Wojtukiewicz MZ: Platelets
and angiogenesis in malignancy. Semin Thromb Hemost. 30:95–108.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ayhan A, Bozdag G, Taskiran C, Gultekin M,
Yuce K and Kucukali T: The value of preoperative platelet count in
the prediction of cervical involvement and poor prognostic
variables in patients with endometrial carcinoma. Gynecol Oncol.
103:902–905. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
TS Z: Applied methodology for
evidence-based medicineCentral South University; 2014
|
|
29
|
Takahashi R, Mabuchi S, Kuroda H, Kozasa
K, Yokoi E, Matsumoto Y and Kimura T: The Significance of
pretreatment thrombocytosis and its association with neutrophilia
in patients with surgically treated endometrial cancer. Int J
Gynecol Cancer. 27:1399–1407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abu-Zaid A, Alsabban M, Abuzaid M, AlOmar
O, Salem H and Al-Badawi IA: Preoperative thrombocytosis as a
prognostic factor in endometrioid-type endometrial carcinoma. Ann
Saudi Med. 37:393–400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Younes G, Segev Y, Begal J, Auslender R,
Goldberg Y, Amit A and Lavie O: The prognostic significance of
hematological parameters in women with uterine serous papillary
carcinoma (USPC). Eur J Obstet Gynecol Reprod Biol. 199:16–20.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakamura K, Nakayama K, Ishikawa M,
Katagiri H, Minamoto T, Ishibashi T, Ishikawa N, Sato E, Sanuki K,
Yamashita H, et al: High pretreatment plasma D-dimer levels are
related to shorter overall survival in endometrial carcinoma. Eur J
Obstet Gynecol Reprod Biol. 201:89–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kizer NT, Hatem H, Nugent EK, Zhou G,
Moore K, Heller P, Mutch DG and Thaker PH: Chemotherapy response
rates among patients with endometrial cancer who have elevated
serum platelets. Int J Gynecol Cancer. 25:1015–1022. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heng S and Benjapibal M: Preoperative
thrombocytosis and poor prognostic factors in endometrial cancer.
Asian Pac J Cancer Prev. 15:10231–10236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Njølstad TS, Engerud H, Werner HM,
Salvesen HB and Trovik J: Preoperative anemia, leukocytosis and
thrombocytosis identify aggressive endometrial carcinomas. Gynecol
Oncol. 131:410–415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsuo K, Yessaian AA, Lin YG, Pham HQ,
Muderspach LI, Liebman HA, Morrow CP and Roman LD: Predictive model
of venous thromboembolism in endometrial cancer. Gynecol Oncol.
128:544–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gorelick C, Andikyan V, Mack M, Lee YC and
Abulafia O: Prognostic significance of preoperative thrombocytosis
in patients with endometrial carcinoma in an inner-city population.
Int J Gynecol Cancer. 19:1384–1389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lerner DL, Walsh CS, Cass I, Karlan BY and
Li AJ: The prognostic significance of thrombocytosis in uterine
papillary serous carcinomas. Gynecol Oncol. 104:91–94. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Scholz HS, Petru E, Gücer F, Haas J,
Tamussino K and Winter R: Preoperative thrombocytosis is an
independent prognostic factor in stage III and IV endometrial
cancer. Anticancer Res. 20:3983–5398. 2000.PubMed/NCBI
|
|
40
|
Gucer F, Moser F, Tamussino K, Reich O,
Haas J, Arikan G, Petru E and Winter R: Thrombocytosis as a
prognostic factor in endometrial carcinoma. Gynecol Oncol.
70:210–214. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tamussino KF, Gucer F, Reich O, Moser F,
Petru E and Scholz HS: Pretreatment hemoglobin, platelet count, and
prognosis in endometrial carcinoma. Int J Gynecol Cancer.
11:236–240. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Luomaranta A, Leminen A and Loukovaara M:
Prediction of lymph node and distant metastasis in patients with
endometrial carcinoma: A new model based on demographics,
biochemical factors, and tumor histology. Gynecol Oncol. 129:28–32.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kaloglu S, Guraslan H, Tekirdag AI,
Dagdeviren H and Kaya C: Relation of preoperative thrombocytosis
between tumor stage and grade in patients with endometrial cancer.
Eurasian J Med. 46:164–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tuomi T, Pasanen A, Luomaranta A, Leminen
A, Bützow R and Loukovaara M: Risk-stratification of endometrial
carcinomas revisited: A combined preoperative and intraoperative
scoring system for a reliable prediction of an advanced disease.
Gynecol Oncol. 137:23–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Borges M, Sculier JP, Paesmans M, Richez
M, Bureau G, Dabouis G, Lecomte J, Michel J, Van Cutsem O,
Schmerber J, et al: Prognostic factors for response to chemotherapy
containing platinum derivatives in patients with unresectable
non-small cell lung cancer (NSCLC). Lung Cancer. 16:21–33. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stone RL, Nick AM, McNeisch IA, Balkwill
F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot
CV, Coward J, et al: Paraneoplastic thrombocytosis in ovarian
cancer. N Engl J Med. 366:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Scambia G, Testa U, Benedetti PP, Foti E,
Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C and
Mancuso S: Prognostic significance of interleukin 6 serum levels in
patients with ovarian cancer. Br J Cancer. 71:354–356. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gastl G, Plante M, Finstad CL, Wong GY,
Federici MG, Bander NH and Rubin SC: High IL-6 levels in ascitic
fluid correlate with reactive thrombocytosis in patients with
epithelial ovarian cancer. Br J Haematol. 83:433–441. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zeimet AG, Marth C, Müller-Holzner E,
Daxenbichler G and Dapunt O: Significance of thrombocytosis in
patients with epithelial ovarian cancer. Am J Obstet Gynecol.
170:549–554. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Knobloch K, Yoon U and Vogt PM: Preferred
0reporting items for systematic reviews and m20eta-analyses
(PRISMA) statement and publication bias. J Craniomaxillofac Surg.
39:91–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
